Zimmer Biomet Archives - Page 9 of 9 - Medical Design Sourcing

Zimmer Biomet names chief transformation officer

Zimmer Biomet (NYSE:ZBH) recently appointed Ellie Humphrey to the newly created position of chief transformation officer, effective Jan. 19.

In the new role, Humphrey will be responsible for connecting key initiatives and implementing a more integrated transformation strategy across the organization. She will report directly to Hanson.

“Ellie’s extensive experience successfully connecting and overseeing global strategic initiatives for multinational corporations will prove invaluable to Zimmer Biomet as we continue to evolve our business to meet the demands of today’s ever-changing healthcare landscape,” president and CEO Bryan Hanson said in a news release. “Her unique insights and deep industry expertise are critical as we continue to drive growth and work to advance our mission to alleviate pain and improve the quality of life for people around the world.”

Prior to joining the company, Humphrey held several leadersh…

The top 5 medtech CEO quotes about COVID-19

The latest earnings season not only provided insights from top medtech CEOs about how the COVID-19 pandemic is changing the industry, but also lessons learned going forward.

Here are five top quotes about lessons learned.

Next>>

DeviceTalks editorial director Tom Salemi contributed to this report.

Zimmer Biomet beats The Street in Q2 results

Zimmer Biomet (NYSE:ZBH) posted second-quarter results today that beat the consensus on Wall Street.

The Warsaw, Ind.-based company report losses of -$208.2 million, or -$1.00 per share, on sales of $1.2 billion for the three months ended June 30, for a bottom-line sales loss of -37% compared with Q2 2019.

Adjusted to exclude one-time items, earnings per share were 5¢, 78¢ ahead of the curve, where analysts were looking for sales of $909.4 million.

“While we are encouraged by our operational performance and the stronger than expected recovery of elective procedures in the second quarter, the impact of COVID-19 is still significant and remains very fluid,” president and CEO Bryan Hanson said in a news release.

“Even in this time of ongoing challenge and uncertainty, we continue to reshape and evolve Zimmer Biomet for greater value and are investing aggressively in our primary growth initiatives and innovative R&D programs to b…

Zimmer Biomet recalls certain implants in Europe over toxin risk

Zimmer Biomet (NYSE:ZBH) has issued a recall for an unspecified number of polyethylene orthopedic implants in Europe due to the possible presence of elevated endotoxin levels.

In a recall notice dated April 30, 2020, but published Thursday, the company said the issue was discovered during routine bacterial endotoxin testing of polyethylene implants. Three polyethylene implant samples during an approximate 6-week period were found to exceed the FDA-adopted standard for endotoxin levels of 20 EU per device. (An EU is a unit of measurement for endotoxin activity, according to the FDA.)

As a result, Zimmer Biomet is recalling certain polyethylene implants for knees, hips and extremities manufactured between December 2016 and January 2017. Possible long-range health consequences include adverse local tissue reaction; critical pain or ache; and severe, systemic reaction to allergen or toxin, according to the recall notice.

The potentially affected products w…

Zimmer Biomet updates remote care system used with Apple Watch

Zimmer Biomet (NYSE:ZBH) this week said it is creating a remote care management system with new MyMobility features on the Apple Watch.

The new features expand upon existing work between Apple and Zimmer Biomet, who launched the care management system in October 2018 to transform pre- and post-operative joint replacement experience.

MyMobility’s features Measure gait quality, and provide healthcare professionals with virtual touchpoints and real-time patient information to enhance decision-making. Patients will continue to receive a connected and customizable experience throughout their care.

Gait metrics are measured using sensors in the Apple watch and iPhone to collect walking speed and double support time while walking on flat-level surfaces, without using GPS. The features will be available to hip and knee joint replacement patients and their healthcare professionals through Zimmer Biomet’s digital platform later this year.

“Digit…

Medartis appoints VP of EMEA

Medartis this week said it appointed Mareike Loch as VP of EMEA, effective August 17.

Loch has more than 23 years of experience in orthopedics. She most recently served as VP of EMEA for the trauma, extremities, foot and ankle, sports medicine and biologics business units at Zimmer Biomet. She has also held a number of leadership roles within Zimmer Biomet’s international business units.

“We are very pleased that following the recent appointment of Lisa Thompson as President North America, Mareike Loch, another proven expert in the field of osteosynthesis, will be joining our executive management board. Mareike is an experienced leader with a strong track record in building and expanding new and developed markets in different cultures. We are convinced that under Mareike’s leadership, we can further strengthen the market proximity of our sales organizations in EMEA, and that she will make an important contribution to our growth,” CEO Christop …

Moody’s lowers its medical device industry earnings forecast

Medical device industry earnings will remain flat over the next 12 to 18 months as people hold off on medical procedures amid the COVID-19 pandemic and resulting recession, according to a new report from Moody’s.

Moody’s had previously projected of 2–4% annual growth.

“While underlying positive trends remain, including ongoing innovation and favorable longterm demographics, we expect some consumers will be slow to return to the healthcare system,” the Moody’s analysts said in the report, out June 11.

“While many procedures are already being rescheduled in certain regions, some consumers will be unable to pay for their procedures due to the economic downturn, as well as their unwillingness to engage with the healthcare system while the coronavirus outbreak persists.”

The predictions from Moody’s come at the same time that medtech industry stocks are taking a hit, along with the overall markets, amid i…

Zimmer Biomet to pay Conformis $9.6m to settle patent disputes

Conformis (NSDQ:CFMS) and Zimmer Biomet (NYSE:ZBH) have agreed to settle all patent disputes over Conformis’ knee and hip replacement products and Zimmer’s knee, shoulder and hip replacement devices, according to an SEC filing today.

The two companies have also agreed to cross-license their respective technologies, and Zimmer Biomet will pay Conformis $9.6 million by January 15, 2021, for the licenses, releases and other immunities that Conformis granted to Zimmer. No payment is due from Conformis to Zimmer.

In August 2019, Billerica, Mass.-based Conformis sued Zimmer Biomet (Warsaw, Ind.) in U.S. District Court in Delaware, alleging infringement of four different patents for personalized joint replacement surgery. Conformis claimed that Zimmer Biomet had infringed its patents for personalized knee and hip replacement surgery and for shoulder arthroplasty.

Conformis was targeting Zimmer Biomet’s Vanguard, Persona, NexGen and Gender Solutions …